Generated by AI
Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function. Its lead candidate, rese-cel, is being studied in the RESET clinical development program across autoimmune conditions including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio also advances CAAR T cell approaches through its broader CABA platform, which is intended to address B cell–mediated autoimmune disorders. Based in Philadelphia, Cabaletta Bio plays a specialized role in the cell therapy market by focusing on precision immunology and disease-modifying treatments for patients with severe autoimmune disease.
Website2929 Arch Street
Philadelphia, PA, 19104
United States
The latest articles about CABA.
Analyst rates Cabaletta Bio a Buy at a $276 million valuation below $299 million cash, though one IEC-HS case could drive 80% or more downside.
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. Click here to read this CABA stock update.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Dec 2's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about CABA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.